22 December 2025VideosAmericasMicheal Hebert, Greenberg Traurig | Chuck Sholtz, Verdiva Bio | Josh Mack, Halozyme | Lawrence Rozsnyai, Metsera
WATCH: Enabling success — overcoming §112 in the new era of life sciences patents
Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
19 February 2026 An EPO appeals board has denied Boston Scientific’s bid to revoke St Jude Medical’s transcatheter aortic valve replacement (TAVR) patent, but declined to hand a complete victory to the patent owner.
13 February 2026 This year’s featured firms and individuals ranked by sister title WIPR, include those instructed on the biggest tech and life sciences cases, as well as the strategists devising global AI patent portfolios.
10 February 2026 Telehealth platform faces legal action from the Danish pharma giant, as well as FDA pressure over GLP-1 drugs and a drop in shares after discontinuing new product.